Gelling compositions for treating malignant tumours and/or preventing tumour recurrence
The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.
1. Gelling composition consisting of:
12 wt % to 30 wt % of at least a poloxamer or mixture of poloxamers, relative to the total weight of the composition;
0.01 wt % to 10 wt % of at least a gelling agent relative to the total weight of the composition; and
0.1 wt % to 10 wt % of at least an anticancer agent,
water,
optionally one or more rheofluidizing agent(s), pharmaceutically acceptable excipient(s), stabilizer(s) or preservative(s), and
optionally one or more another therapeutic agent,
wherein the gelling agent is selected from the group consisting of chitosan and derivatives thereof, carrageenan and derivatives thereof, alginate and derivatives thereof, pectin and derivatives thereof, fibrin and derivatives thereof, homo- and copolymers of acrylic acid crosslinked with a polyalkenyl polyether, or mixtures thereof,
wherein the optional pharmaceutically acceptable excipient is selected from the group consisting of propylene glycol, salts or bioadhesive agents selected from hydroxypropyl methylcellulose, methylcellulose or cross-linked acrylic acid polymers,
wherein the optional stabilizer is selected from the group consisting of surfactants, polymers, polyols, a poloxamer, albumin, gelatin, trehalose, proteins, sugars, polyvinylpyrrolidone, N-acetyl-tryptophan (“NAT”), caprylat, a polysorbate, amino acids, and divalent metal cations,
wherein the optional preservative is selected from the group consisting of benzyl alcohol, cresols, benzoic acid, phenol, parabens and sorbic acid,
wherein the gelling composition is a homogenous aqueous gelling composition, and
wherein the gelling composition is in the form of a spray, an injectable solution, or a spreadable solution.
2. The gelling composition of claim 1 , wherein the gelling temperature of the composition is of between 20° C. and 40° C.
3. The gelling composition of claim 1 , wherein the gelling agent is selected from the group consisting of alginate, pectin and fibrin or mixtures thereof.
4. The gelling composition of claim 1 , wherein the anticancer agent is selected from the group consisting of 5-FU (fluorouracil), oxaliplatin, cisplatin, folinic acid, irinotecan, metformin, paclitaxel, topotecan, etoposide, ifosfamide, altretamine, doxorubicin, tamoxifen, tamoxifen citrate, gemcitabine and mixtures thereof, or a mixture of 5-FU and cis-platin, a mixture of 5-FU and oxaliplatin, a mixture of 5-FU and folinic acid, a mixture of 5-FU, folinic acid and oxaliplatin, a mixture of oxaliplatin and paclitaxel or a mixture of cisplatin and paclitaxel.
5. The gelling composition of claim 1 , wherein the rheofluidizing agent is present in the composition.
6. The gelling composition of claim 1 , wherein the one or more therapeutic agents are selected from the group consisting of 5-FU (fluorouracil), oxaliplatin, cisplatin, folinic acid, irinotecan, metformin, paclitaxel, topotecan, etoposide, ifosfamide, altretamine, doxorubicin, tamoxifen, tamoxifen citrate, gemcitabine and mixtures thereof, or a mixture of 5-FU and cis-platin, a mixture of 5-FU and oxaliplatin, a mixture of 5-FU and folinic acid, a mixture of 5-FU, folinic acid and oxaliplatin, a mixture of oxaliplatin and paclitaxel or a mixture of cisplatin and paclitaxel, wherein the one or more therapeutic agent are different from the anticancer agent.